Hong Kong Hospitality Stock News

Air China has launched a new direct passenger route between Chengdu and Brussels, creating a fresh air link between China and Belgium. The service is intended to support international connectivity and contribute to the recovery of inbound tourism in Chengdu. The new route forms part of Air China’s wider international network development and aligns with local infrastructure and travel facilitation efforts. For investors tracking Air China (SEHK:753), the new Chengdu to Brussels route lands...

Phase 2 data on UBT251 puts United Laboratories International Holdings in focus United Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data for UBT251 in China, showing HbA1c and body weight reductions against placebo and semaglutide in type 2 diabetes patients. The topline readout matters because it moves UBT251 closer to late stage development, supports the start of phase 3 trials in China, and ties directly into the company’s broader diabetes...

China Mengniu Dairy (SEHK:2319) has come into focus after releasing its full year 2025 results and proposing a final ordinary dividend of RMB 0.52 per share, subject to shareholder approval. See our latest analysis for China Mengniu Dairy. The latest earnings and dividend proposal appear to have supported sentiment, with a 30 day share price return of 6.36% and a 90 day share price return of 14.41% lifting the stock to HK$17.55. This comes even though the 1 year total shareholder return is a...

China Star Entertainment (SEHK:326) just released full year 2025 results showing revenue of HK$404.92 million and a net loss of HK$443.76 million, broadly in line with guidance for a sizeable annual loss. See our latest analysis for China Star Entertainment. The weak 2025 results come after a sharp re-rating in the market, with the share price at HK$6.70 and a 30 day share price return of 45.34%. This has fed into a very large 1 year total shareholder return, suggesting momentum has been...

Simcere Pharmaceutical Group (SEHK:2096) has drawn fresh attention after reporting full year 2025 sales of CN¥7,731.41 million and net income of CN¥1,344.01 million, alongside a proposed final dividend of CN¥0.18 per share. See our latest analysis for Simcere Pharmaceutical Group. At a latest share price of HK$13.62, Simcere Pharmaceutical Group has seen a 16.91% 1 month share price return and an 80.98% 1 year total shareholder return. Recent earnings, dividend and leadership announcements...

Today is shaping up negative for Contiocean Environment Tech Group Co., Ltd. ( HKG:2613 ) shareholders, with the...

Sinotruk (Hong Kong) (SEHK:3808) has drawn fresh attention after reporting full year 2025 results with higher sales and net income, along with a board proposal to lift the ordinary final dividend for shareholders. See our latest analysis for Sinotruk (Hong Kong). The share price has responded strongly, with a 30 day share price return of 14.48% and a 90 day gain of 51.71%. The 1 year total shareholder return of 137.59% points to building momentum around the healthier earnings and higher...

Ubtech Robotics Corp Ltd ( HKG:9880 ) shareholders will have a reason to smile today, with the analysts making...

Market forces rained on the parade of NetDragon Websoft Holdings Limited ( HKG:777 ) shareholders today, when the...

Today is shaping up negative for Kingsoft Corporation Limited ( HKG:3888 ) shareholders, with the analysts delivering a...

One thing we could say about the analysts on West China Cement Limited ( HKG:2233 ) - they aren't optimistic, having...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

One thing we could say about the covering analyst on Beijing Chunlizhengda Medical Instruments Co., Ltd. ( HKG:1858...

The latest analyst coverage could presage a bad day for China Datang Corporation Renewable Power Co., Limited...

Jiaxin International Resources Investment Limited ( HKG:3858 ) shareholders will have a reason to smile today, with the...

Earnings shift draws fresh attention to InnoCare Pharma InnoCare Pharma (SEHK:9969) has drawn fresh attention after reporting full year 2025 sales of CN¥2,374.91 million and net income of CN¥642.47 million, compared with a net loss a year earlier. See our latest analysis for InnoCare Pharma. The earnings swing has coincided with strong price momentum, with a 31.19% 1 month share price return and a 24.16% year to date share price return at HK$15.52. The 1 year total shareholder return of...

Fosun International (SEHK:656) has come under closer focus after reporting a larger net loss for 2025, withholding a dividend for the year, and outlining a higher dividend payout framework starting from the 2026 financial year. See our latest analysis for Fosun International. The recent dividend decision and larger 2025 net loss come after a mixed share price pattern, with a 19.5% 1 month share price return and a 9.91% 1 year total shareholder return contrasting with weaker multi year total...

Recent share performance and business snapshot Ascentage Pharma Group International (SEHK:6855) has drawn investor attention after recent share price moves, with returns of about 13% over the past week and 15% over the past month. The Suzhou based clinical stage biotech focuses on therapies for cancers, chronic hepatitis B and age related diseases in Mainland China. It generated HK$574.12 million in revenue and reported a net loss of HK$1,242.77 million. See our latest analysis for Ascentage...

Why Angelalign Technology’s latest earnings and dividends matter for investors Angelalign Technology (SEHK:6699) has drawn fresh attention after releasing full year 2025 earnings, alongside a proposed special dividend of HK$4.99 per share and affirming its regular annual payout. See our latest analysis for Angelalign Technology. Since these results and dividend announcements, the share price has gained momentum, with a 30 day share price return of 11.71%, a year to date share price return of...

Those following along with Shenzhou International Group Holdings Limited ( HKG:2313 ) will no doubt be intrigued by the...

The market seemed underwhelmed by last week's earnings announcement from Guangdong Kanghua Healthcare Group Co., Ltd...

The recent earnings posted by China Hongguang Holdings Limited ( HKG:8646 ) were solid, but the stock didn't move as...

As global markets navigate the complexities of Middle East tensions and energy market volatility, Asian small-cap stocks present intriguing opportunities amid a backdrop of mixed economic signals. With key indices showing resilience and geopolitical uncertainties influencing investor sentiment, identifying promising small-cap companies requires a focus on those with robust fundamentals and strategic insider actions that align with current market dynamics.

The analysts covering C&D International Investment Group Limited ( HKG:1908 ) delivered a dose of negativity to...